Single-Arm Studies Can Have Adaptive Designs, Industry Tells FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent draft guidance on adaptive device trial designs is a good step, but it should be more inclusive of single-arm studies and not just randomized trials, AdvaMed says.
You may also be interested in...
Adaptive Study Design OK For Single-Arm Trials, FDA Says
A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.